ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
TrxR2 Lactylation Facilitates Mitochondrial Protection and Endothelial Ferroptosis Resistance in Diabetic Cardiomyopathy.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Thioredoxin reductase 2 (TrxR2), a radical-trapping antioxidant, plays a critical role in cardiac defense. However, the mechanisms underlying its benefits remain unclear. In this study, we aimed to investigate whether endothelial TrxR2 prevents cardiac microvascular dysfunction in diabetic cardiomyopathy (DCM). Key genes in the thioredoxin family and those involved in ferroptosis were analyzed using bulk RNA-sequencing assay. Diabetic injury was induced in multiple transgenic mouse models, including endothelial cell-specific knockout mice for TrxR2, sterol carrier protein 2 (SCP2), and Tu translation elongation factor, mitochondrial (TUFM). The TrxR2 lactylation site was identified by mass spectrometry and verified by a custom-made lactylation antibody. Mitochondrial thioredoxin reductase (mitoTrxR) activity and lipid peroxyl radicals were detected using fluorescence staining. Endothelial TrxR2 deficiency significantly suppressed mitoTrxR activity, exacerbated cardiac microvascular dysfunction, and accelerated DCM progression. In contrast, TrxR2 overexpression and Kukoamine B (TrxR2 agonist) treatment inhibited mitochondria-associated ferroptosis by facilitating SCP2 degradation and blocking the mitochondrial translocation of acyl-CoA synthetase long-chain family member 4 (ACSL4) via mitophagy. Mechanistically, TrxR2 maintained TUFM expression by scavenging oxygen radicals, thereby facilitating the mitochondrial translocation of AMPK for mitophagy activation. TrxR2 undergoes lactylation at lysine 340. This process is mediated by mitochondrial alanyl-tRNA synthetase 2 (AARS2) and lactate accumulation in both human and mouse diabetic hearts. This modification and sodium lactate administration compensatorily enhanced mitoTrxR activity, promoted mitophagy, and conferred ferroptosis resistance in cardiac microcirculation in DCM. Our findings demonstrate that TrxR2 and its lactylation modification promote mitophagy, enhance ferroptosis resistance, and improve cardiac microvascular function in DCM. Thus, this study provides a promising therapeutic approach for the management of diabetic complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.